IgA nephropathy
Conditions
Interventions
ARB valsartan
ACE-I enalapril
Sponsors
ARB therapeutic society of IgA nephropathy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)patients with IgA nephropathy proven by renal biopsy 2)patients aged over 16 years and 75 years or less 3)patients who have urinary protein of over 0.5g/day 4)Patients with a serum creatinine value of 3mg/dL or less. 5)IgA nephropathy patients with hypertension (over 140 mmHg in SBP and over 90 mmHg in DBP) treated with or without antihypertensive agents except ARBs and ACE-Is.
Exclusion criteria
Exclusion criteria: 1)patients with nephrotic syndorome. 2)patients who administered steroid or discontinuted within 6 months prior to enrolment in the study. 3)patients with serious liver dysfunction. 4)pregnant women or women of child bearing potential and nursing women. 5)patients with hypersensitivity to angiotensin II receptor blocker and angiotensin convertig enzyme inhibitor. 6)Other patients who are judged to be inappropriate for the study by the investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)change in Ccr,2)inverse of inclination of serum Cr value, 3)change in urinary protein excretion, 4)inidence of events (doubling of serum creatinine concentration, 50% decrease in Ccr from the baseline value, dialysis) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)change in PRA and PCA, 2)hyperkalemia, 3)tolerability (drug discontinuation rate) | — |
Countries
Japan
Contacts
Public ContactYoichi Miyazaki
The Jikei University School of Medicine Department of Internal Medicine
Outcome results
None listed